NEW YORK (GenomeWeb) – Illumina said today that an expanded version of its VeriSeq NIPT software to analyze fetal aneuploidies has met the requirements of the EU's in vitro diagnostic directive and it will apply the CE mark to the software.

The VeriSeq NIPT test is a noninvasive prenatal test that analyzes fetal aneuploidy for chromosomes 21, 18, 13, as well as the sex chromosomes.

The updated software includes a new method for processing samples and an increase in the number of samples it can batch from 16 to 48.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.